SABSW SAB Biotherapeutics, Inc. - Warrant
NASDAQ · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 6, 2026
$0,01
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$0,0052-Wochen-Tief
$0,0552-Wochen-Hoch
Marktkapitalisierung (MRQ)
$1M
P/E
-0.0
EPS
$-0.79
Umsatz
$0
Ihre Abzeichen
52W-Spanne
$0–$0
Analystenbewertung
·
Kursziel
·
P/E
-0.0
ROE
16.2%
Nettogewinnmarge
·
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
SABSW Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$0.01
Marktkapitalisierung (MRQ)
$1M
P/E
-0.0
EPS
$-0.79
Umsatz
$0
ROE
16.2%
Verschuldungsgrad
0.0
52W-Spanne
$0–$0
SABSW Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$02020-12-31 → 2025-12-31
EPS$-0.792020-12-31 → 2025-12-31
Freier Cashflow$-46M2021-12-31 → 2025-12-31
Nettogewinnmarge·2021-12-31 → 2024-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | SABSW | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -0.0 | · | · | · | |
| K/B (MRQ) | 0.0 | · | · | · | |
| EV / EBITDA | 2.1 | · | · | · | |
| Price / FCF (Kurs / FCF) | -0.0 | · | · | · | |
| Price / Cash Flow (Kurs / Cashflow) | -0.0 | · | · | · | |
| EV / FCF | 2.1 | · | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 0.0 | · | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | SABSW | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| ROA | 12.2%5-Jahres-Durchschnitt ≈-34.5% | ≈-34.5% | · | · | |
| ROE | 16.2%5-Jahres-Durchschnitt ≈-69.5% | ≈-69.5% | · | · | |
| ROIC | -32.3% | · | · | · |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | SABSW | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Debt / Equity (Fremdkapital / Eigenkapital) | 0.05-Jahres-Durchschnitt ≈0.0 | ≈0.0 | · | · | |
| Liquiditätsgrad (MRQ) | 9.25-Jahres-Durchschnitt ≈6.0 | ≈6.0 | · | · | |
| Quick Ratio | 9.05-Jahres-Durchschnitt ≈5.6 | ≈5.6 | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | SABSW | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | -40.9%5-Jahres-Durchschnitt ≈-64.1% | ≈-64.1% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | -72.1% | · | · | · | |
| Net Income CAGR 5Y (Nettoergebnis CAGR 5J) | -8.0% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | SABSW | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.05-Jahres-Durchschnitt ≈0.0 | ≈0.0 | · | · | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$0.00 | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1M | $2M | $24M | $61M | $55M | |
| R&D Expense | $34M | $30M | $17M | $36M | $57M | $28M | |
| SG&A Expense | $15M | $14M | $24M | $16M | $17M | $7M | |
| Operating Expenses | $49M | $44M | $40M | $53M | $74M | $35M | |
| Operating Income | $-49M | $-43M | $-38M | $-29M | $-13M | $21M | |
| Interest Expense | · | · | $315.3K | $301.6K | $294.5K | $469.2K | |
| Other Non-op | $62M | $9M | $-4M | $10M | $5.5K | $4.0K | |
| Pretax Income | $13M | · | $-42M | $-19M | $-17M | $20M | |
| Income Tax | $0 | $0 | $0 | $25.6K | $0 | $0 | |
| Net Income | $13M | $-34M | $-42M | $-19M | $-17M | $20M | |
| EPS (Basic) | $0.22 | $-3.68 | $-7.64 | $-4.31 | $-0.63 | $0.79 | |
| EPS (Diluted) | $-0.79 | $-3.68 | $-7.64 | $-4.31 | $-0.63 | $0.74 | |
| Shares (Basic) | 19,311,798 | 9,261,918 | 5,521,487 | 4,352,497 | 27,339,180 | 25,391,084 | |
| Shares (Diluted) | 61,340,193 | 9,261,918 | 5,521,487 | 4,352,497 | 27,339,180 | 27,011,482 | |
| EBITDA | $-46M | $-38M | $-34M | · | $-12M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $9M | $57M | $15M | $33M | $13M | |
| Short-term Investments | $86M | $12M | $0 | · | · | · | |
| Receivables | · | · | $0 | $6M | $8M | $21M | |
| Prepaid Expense | $4M | $3M | $2M | $1M | $3M | $1M | |
| Current Assets | $101M | $24M | $59M | $22M | $50M | $34M | |
| PP&E (Net) | $13M | $15M | $20M | $23M | $24M | $15M | |
| PP&E (Gross) | $31M | $30M | $30M | $30M | $28M | · | |
| Accum. Depreciation | $18M | $15M | $10M | $6M | $3M | $2M | |
| Total Assets | $173M | $44M | $84M | $51M | $81M | $57M | |
| Accounts Payable | $3M | $2M | $945.9K | $4M | $4M | $7M | |
| Accrued Liabilities | · | · | · | · | · | $156.2K | |
| Short-term Debt | $0 | $275.8K | $1M | $772.7K | $2M | $538.7K | |
| Current Liabilities | $11M | $8M | $11M | $15M | $26M | $11M | |
| Capital Leases | $2M | $581.1K | $635.8K | $361.2K | $2M | $2M | |
| Total Liabilities | $21M | $18M | $27M | $20M | $43M | $18M | |
| Total Debt | $0 | $275.8K | $1M | · | $2M | · | |
| Common Stock | $5.0K | $935 | $929 | $510 | $4.3K | $2.6K | |
| Paid-in Capital | $268M | $156M | $153M | $84M | $68M | $51M | |
| Retained Earnings | $-111M | $-124M | $-90M | $-48M | $-29M | $-12M | |
| Treasury Stock | $6M | $6M | $6M | $6M | $0 | · | |
| AOCI | $187.0K | $-135.4K | $26.4K | · | · | · | |
| Stockholders' Equity | $151M | $26M | $57M | $31M | $39M | $39M | |
| Liabilities + Equity | $173M | $44M | $84M | $51M | $81M | $57M | |
| Shares Outstanding | 47,609,899 | 9,288,868 | 9,225,494 | 5,040,236 | 43,487,279 | 25,973,406 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | $3M | $5M | $4M | $3M | $1M | $383.1K | |
| Stock-based Comp | $5M | $3M | $2M | $3M | $2M | $1M | |
| Other Non-cash | $-66M | $-8M | $11M | · | $15M | · | |
| Operating Cash Flow | $-45M | $-34M | $-25M | $-23M | $2M | $10M | |
| CapEx | $933.2K | $337.3K | $197.2K | $2M | $11M | $13M | |
| Investing Cash Flow | $-122M | $-12M | $-152.7K | $-2M | $-11M | $-13M | |
| Stock Issued | · | · | · | $8M | $0 | $10M | |
| Net Stock Activity | · | · | · | · | $0 | · | |
| Financing Cash Flow | $168M | $-1M | $67M | $1M | $36M | $9M | |
| Net Change in Cash | $2M | $-48M | $42M | $-24M | $27M | $6M | |
| Free Cash Flow | $-46M | $-35M | $-25M | · | $-9M | · | |
| Levered FCF | · | · | $-26M | · | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | · | -3244.9% | -1700.6% | · | -22.0% | · | |
| Net Margin | · | -2579.0% | -1884.5% | · | -28.2% | · | |
| Pretax Margin | · | · | -1884.5% | · | -28.2% | · | |
| EBITDA Margin | · | -2889.0% | -1537.4% | · | -19.6% | · | |
| ROA | 12.2% | -53.2% | -62.6% | · | -17.2% | · | |
| ROE | 16.2% | -108.5% | -116.3% | · | -46.6% | · | |
| ROIC | -32.3% | · | -65.2% | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 9.5 | 3.0 | 5.4 | · | 1.9 | 0.3 | |
| Quick Ratio | 9.0 | 2.6 | 5.2 | · | 1.6 | 0.3 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | · | 0.0 | · | |
| Interest Coverage | · | · | -120.8 | · | -45.5 | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | · | 0.6 | · | |
| Receivables Turnover | · | · | 0.8 | · | 4.3 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.18 | $2.80 | $6.21 | · | $0.89 | $0.01 | |
| Revenue / Share | $0.00 | $0.14 | $0.41 | · | $2.23 | · | |
| Cash Flow / Share | $-0.73 | $-3.70 | $-4.55 | · | $0.07 | · | |
| Cash / Share | $0.22 | $0.96 | $6.13 | · | $0.76 | $0.03 | |
| EPS (TTM) | $-0.79 | $-3.68 | $-7.64 | $-4.31 | $-0.63 | $0.74 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | · | -40.9% | -90.6% | -60.7% | 10.2% | · | |
| Revenue CAGR 3Y | · | -72.1% | -65.6% | · | · | · | |
| Net Income CAGR 5Y | -8.0% | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $1M | $2M | $24M | $61M | $55M | |
| Net Income TTM | $13M | $-34M | $-42M | $-19M | $-17M | $20M | |
| Market Cap | $1M | · | · | · | · | · | |
| Enterprise Value | $-95M | · | · | · | · | · | |
| P/E | -0.0 | · | · | · | · | · | |
| P/B | 0.0 | · | · | · | · | · | |
| P / Tangible Book | 0.0 | · | · | · | · | · | |
| P / Cash Flow | -0.0 | · | · | · | · | · | |
| P / FCF | -0.0 | · | · | · | · | · | |
| EV / EBITDA | 2.1 | · | · | · | · | · | |
| EV / FCF | 2.1 | · | · | · | · | · | |
| Earnings Yield | -3390.6% | · | · | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $114.7K | $0 | $263.1K | $944.6K | $305.0K | $1M | $85.5K | $581.1K | $2M | $4M | |
| R&D Expense | $16M | $13M | $11M | $9M | $7M | $8M | $7M | $8M | $7M | $8M | $4M | $4M | $4M | $5M | $7M | $7M | |
| SG&A Expense | $7M | $7M | $5M | $4M | $3M | $3M | $3M | $3M | $4M | $4M | $15M | $3M | $3M | $3M | $3M | $4M | |
| Operating Expenses | $23M | $20M | $16M | $13M | $10M | $11M | $10M | $11M | $10M | $12M | $19M | $7M | $7M | $8M | $10M | $11M | |
| Operating Income | $-23M | $-20M | $-16M | $-13M | $-10M | $-11M | $-10M | $-11M | $-10M | $-11M | $-19M | $-5M | $-6M | $-7M | $-8M | $-8M | |
| Interest Expense | · | · | · | · | · | · | · | · | $93.1K | $76.4K | · | $69.7K | $75.3K | $92.4K | $87.7K | $70.6K | |
| Other Non-op | $886.0K | $1M | $-1M | $58M | $-382.0K | $6M | $-1M | $960.0K | $3M | $6M | $-4M | $220.6K | $-404.3K | $48.2K | $11.0K | $731.2K | |
| Pretax Income | · | · | · | · | · | · | · | $-10M | $-7M | $-5M | · | $-5M | $-7M | $-7M | $-8M | $-7M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | |
| Net Income | $-22M | $-19M | $-17M | $45M | $-10M | $-5M | $-11M | $-10M | $-7M | $-5M | $-23M | $-5M | $-7M | $-7M | $-8M | $-7M | |
| EPS (Basic) | $-0.28 | $-0.35 | $1.37 | $0.50 | $-1.09 | $-0.56 | $-1.23 | $-1.12 | $-0.79 | $-0.54 | $-3.85 | $-0.97 | $-1.36 | $-1.46 | $-4.06 | $-0.16 | |
| EPS (Diluted) | $-0.28 | $-0.35 | $1.07 | $-0.21 | $-1.09 | $-0.56 | $-1.23 | $-1.12 | $-0.79 | $-0.54 | $-3.85 | $-0.97 | $-1.36 | $-1.46 | $-4.06 | $-0.16 | |
| Shares (Basic) | 79,753,100 | 53,558,639 | · | 10,660,500 | 9,294,469 | 9,291,641 | · | 9,259,192 | 9,255,025 | 9,241,940 | · | 5,240,600 | 5,042,126 | 5,039,705 | · | 43,030,885 | |
| Shares (Diluted) | 79,753,100 | 53,558,639 | · | 77,863,263 | 9,294,469 | 9,291,641 | · | 9,259,192 | 9,255,025 | 9,241,940 | · | 5,240,600 | 5,042,126 | 5,039,705 | · | 43,030,885 | |
| EBITDA | $-23M | $-19M | · | $-12M | $-9M | $-10M | · | $-10M | $-9M | $-9M | · | $-4M | $-6M | $-7M | · | $-7M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8M | $21M | $11M | $29M | $4M | $6M | $9M | $9M | $17M | $14M | $57M | $2M | $8M | $13M | $15M | $8M | |
| Short-term Investments | $94M | $87M | $86M | $81M | $2M | $7M | $12M | $21M | $20M | $30M | $0 | · | · | · | · | · | |
| Receivables | · | · | · | · | · | · | · | · | · | · | · | $0 | $364.1K | $763.1K | $6M | · | |
| Prepaid Expense | $3M | $4M | $4M | $2M | $4M | $3M | $3M | $2M | $2M | $3M | $2M | $702.2K | $867.6K | $1M | $1M | $907.9K | |
| Current Assets | $108M | $113M | $101M | $113M | $9M | $16M | $24M | $33M | $40M | $47M | $59M | $3M | $9M | $15M | $22M | $22M | |
| PP&E (Net) | $14M | $14M | $13M | $13M | $14M | $15M | $15M | $16M | $17M | $18M | $20M | $21M | $22M | $22M | $23M | $24M | |
| PP&E (Gross) | $33M | $32M | $31M | $30M | $30M | $30M | $30M | $30M | $30M | $30M | $30M | $30M | $30M | $30M | $30M | $29M | |
| Accum. Depreciation | $19M | $18M | $18M | $17M | $16M | $15M | $15M | $14M | $13M | $12M | $10M | $9M | $8M | $7M | $6M | $5M | |
| Total Assets | $238M | $248M | $173M | $183M | $30M | $38M | $44M | $54M | $62M | $71M | $84M | $28M | $35M | $43M | $51M | $53M | |
| Accounts Payable | $4M | $4M | $3M | $3M | $3M | $3M | $2M | $1M | $1M | $1M | $945.9K | $1M | $1M | $1M | $4M | $5M | |
| Short-term Debt | · | · | $0 | $0 | $0 | $138.6K | $275.8K | $0 | $615.8K | $835.5K | $1M | $541.6K | $111.9K | $444.5K | $772.7K | $25.0K | |
| Current Liabilities | $12M | $10M | $11M | $11M | $11M | $10M | $8M | $9M | $8M | $8M | $11M | $9M | $11M | $14M | $15M | $17M | |
| Capital Leases | $1M | $2M | $2M | $2M | $2M | $2M | $581.1K | $682.9K | $782.4K | $554.5K | $635.8K | $0 | $91.8K | $227.7K | $361.2K | $762.8K | |
| Total Liabilities | $23M | $21M | $21M | $18M | $18M | $17M | $18M | $17M | $16M | $19M | $27M | $13M | $16M | $18M | $20M | $22M | |
| Total Debt | · | · | · | $0 | $0 | $138.6K | · | $0 | $615.8K | $835.5K | · | $541.6K | $111.9K | $444.5K | · | $25.0K | |
| Common Stock | $8.0K | $7.6K | $4.8K | $4.8K | $936 | $936 | $935 | $929 | $929 | $929 | $929 | $5.3K | $5.3K | $5.1K | $510 | $4.4K | |
| Paid-in Capital | $373M | $363M | $268M | $265M | $157M | $156M | $156M | $155M | $154M | $153M | $153M | $88M | $87M | $85M | $84M | $76M | |
| Retained Earnings | $-152M | $-130M | $-111M | $-94M | $-139M | $-129M | $-124M | $-113M | $-102M | $-95M | $-90M | $-67M | $-62M | $-55M | $-48M | $-40M | |
| Treasury Stock | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | |
| AOCI | $-930.0K | $-222.8K | $186.5K | $71.2K | $-15.8K | $-111.6K | $-135.4K | $52.1K | $-31.4K | $-63.4K | $26.4K | · | · | · | · | · | |
| Stockholders' Equity | $215M | $227M | $151M | $165M | $12M | $21M | $26M | $37M | $46M | $53M | $57M | $15M | $20M | $24M | $31M | $31M | |
| Liabilities + Equity | $238M | $248M | $173M | $183M | $30M | $38M | $44M | $54M | $62M | $71M | $84M | $28M | $35M | $43M | $51M | $53M | |
| Shares Outstanding | 83,493,068 | 75,744,576 | 47,609,899 | 47,493,994 | 9,291,697 | 9,291,697 | 9,288,868 | 9,229,274 | 9,229,274 | 9,229,274 | 9,225,494 | 52,319,156 | 52,314,656 | 50,397,762 | 5,040,236 | 43,030,885 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $800.0K | $731.0K | $738.2K | $700.0K | $800.0K | $756.6K | $842.7K | $900.0K | $1M | $2M | $854.7K | $1M | $900.0K | $898.5K | $893.2K | $890.0K | |
| Stock-based Comp | $7M | $5M | $3M | $800.8K | $627.2K | $613.0K | $674.1K | $1M | $601.4K | $617.4K | $536.9K | $639.2K | $644.8K | $602.8K | $628.5K | $578.2K | |
| Other Non-cash | · | $-2M | · | · | · | $-4M | · | · | · | $-8M | · | · | · | $4M | · | · | |
| Operating Cash Flow | $-10M | $-14M | $-17M | $-13M | $-7M | $-8M | $-10M | $-6M | $-8M | $-11M | $-13M | $-5M | $-5M | $-2M | $-2M | $-6M | |
| CapEx | $2M | $983.3K | · | · | · | · | $55.4K | $100.3K | $52.5K | $129.1K | $67.9K | $85.3K | $22.7K | $21.3K | $117.8K | $78.5K | |
| Investing Cash Flow | $-5M | $-66M | $-2M | $-130M | $5M | $5M | $9M | $-1M | $11M | $-31M | $-67.9K | $-40.9K | $-22.7K | $-21.3K | $-117.8K | $-78.5K | |
| Financing Cash Flow | $2M | $90M | $-41.7K | $169M | $-173.8K | $-174.0K | $217.0K | $-674.1K | $-321.0K | $-394.4K | $68M | $-140.3K | $-363.8K | $-359.8K | $8M | $-2M | |
| Net Change in Cash | $-12M | $10M | $-19M | $26M | $-2M | $-3M | $-273.2K | $-8M | $3M | $-43M | $54M | $-5M | $-5M | $-2M | $7M | $-8M | |
| Free Cash Flow | · | $-15M | · | · | · | · | · | · | · | $-11M | · | · | · | $-2M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-2M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | -3877.0% | -1205.9% | · | -420.0% | -7573.4% | -1273.8% | · | -217.5% | |
| Net Margin | · | · | · | · | · | · | · | · | -2787.7% | -532.1% | · | -402.6% | -8046.1% | -1265.5% | · | -197.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | -2787.7% | -532.1% | · | -402.6% | -8046.1% | -1265.5% | · | -197.1% | |
| EBITDA Margin | · | · | · | · | · | · | · | · | -3496.9% | -998.1% | · | -344.2% | -6556.1% | -1119.2% | · | -192.8% | |
| ROA | -16.8% | -13.2% | · | 38.3% | -22.0% | -9.5% | · | -25.2% | -15.1% | -8.8% | · | -12.6% | -14.5% | -13.4% | · | -8.3% | |
| ROE | -19.8% | -15.2% | · | 45.0% | -34.8% | -14.0% | · | -39.7% | -22.3% | -13.0% | · | -22.2% | -24.2% | -22.4% | · | -66.3% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | · | -32.7% | -29.8% | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.2 | 11.4 | · | 10.5 | 0.9 | 1.7 | · | 3.7 | 5.2 | 5.7 | · | 0.3 | 0.8 | 1.1 | · | 1.3 | |
| Quick Ratio | 8.8 | 10.9 | · | 10.3 | 0.5 | 1.3 | · | 3.4 | 4.9 | 5.3 | · | 0.3 | 0.7 | 1.0 | · | 0.5 | |
| Debt / Equity | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -109.6 | -149.1 | · | -76.4 | -86.0 | -80.1 | · | -110.5 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | · | · | · | · | · | 0.5 | 1.5 | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.57 | $3.00 | · | $3.48 | $1.29 | $2.30 | · | $4.00 | $5.00 | $5.72 | · | $0.29 | $0.38 | $0.48 | · | $0.71 | |
| Revenue / Share | · | · | · | · | · | · | · | · | $0.03 | $0.10 | · | $0.02 | · | $0.01 | · | $0.08 | |
| Cash Flow / Share | · | $-0.27 | · | · | · | $-0.84 | · | · | · | $-1.16 | · | · | · | $-0.03 | · | · | |
| Cash / Share | $0.10 | $0.27 | · | $0.62 | $0.40 | $0.61 | · | $0.99 | $1.87 | $1.52 | · | $0.05 | $0.15 | $0.26 | · | $0.19 | |
| EPS (TTM) | $0.23 | $-0.58 | · | $-3.09 | $-4.00 | $-3.70 | · | $-6.30 | $-6.15 | $-6.72 | · | $-7.85 | $-7.04 | $-5.79 | · | $-0.66 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1M | $1M | · | $1M | $1M | $1M | · | $2M | $3M | $3M | · | $4M | $6M | $13M | · | $33M | |
| Net Income TTM | $-13M | $-398.3K | · | $19M | $-37M | $-34M | · | $-46M | $-40M | $-40M | · | $-27M | $-29M | $-27M | · | $-22M | |
| Market Cap | $3M | $3M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 0.2 | -0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/S | 2.3 | 2.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -0.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 642.5% | -1620.1% | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-06-30 |
|---|---|---|---|---|---|
| Umsatz | $0 | $1M | $2M | $24M | · |
| Betriebsgewinnmarge % | · | -3244.9% | -1700.6% | · | · |
| Nettoergebnis | $13M | $-34M | $-42M | $-19M | · |
| Verwässerte EPS | $-0.79 | $-3.68 | $-7.64 | $-4.31 | · |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-06-30 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.0 | 0.0 | 0.0 | · | · |
| Liquiditätsgrad | 9.5 | 3.0 | 5.4 | · | · |
| Quick Ratio | 9.0 | 2.6 | 5.2 | · | · |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-06-30 |
|---|---|---|---|---|---|
| Freier Cashflow | $-46M | $-35M | $-25M | · | · |
Institutionelle Eigentümer (13F) 10 Einreicher · $14K gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
10
Gehaltener Wert
$14K
Neue Positionen
2
Geschlossene Positionen
0
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 2 (0 vs. Vorquartal) | 0 (-2 vs. Vorquartal) | 4 (+4 vs. Vorquartal) | 0 (-2 vs. Vorquartal) | +26K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| LMR Partners LLP | $6.907 | 539.588 | 49,74% | Aktien |
| CLEAR STREET LLC | $2.625 | 78.833 | 18,90% | Aktien |
| MORGAN STANLEY | $1.874 | 146.439 | 13,50% | Aktien |
| Clear Street Group Inc. | $1.012 | 79.033 | 7,29% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $800 | 62.500 | 5,76% | Kaufoption |
| GTS SECURITIES LLC | $537 | 41.301 | 3,87% | Aktien |
| UBS Group AG | $85 | 6.567 | 0,61% | Aktien |
| WOLVERINE ASSET MANAGEMENT LLC | $42 | 3.289 | 0,30% | Aktien |
| TORONTO DOMINION BANK | $4 | 300 | 0,03% | Aktien |
| Virtu Financial LLC | $0 | 21.223 | 0,00% | Aktien |
Aktivisten & 5%+-Eigentümer 3 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P. ×2 Einreichungen | 10. August 2026 | 9,90% | Änderung | · | SEC |
| Christine Hamilton, Edward Hamilton | 1. November 2021 | · | Erste Einreichung | Passive Anlage | SEC |
| Eddie J. Sullivan, PhD | 1. November 2021 | · | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 1 Insider · 1 Führungskräfte · 0 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Alexandra Kropotova | CHIEF MEDICAL OFFICER | 17. September 2026 F | 41.853 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026